Double Protease Inhibitor to Darunavir Switch Study
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to study the effects of switching from an antiretroviral
combination that includes two ritonavir boosted protease inhibitors to replacement of these
two protease inhibitors with a new protease inhibitor called Darunavir (also boosted with
ritonavir).
The study will investigate the effect of the switch on viral load (the levels of the HIV
virus in the blood), on immunological parameters (CD4 count) and on other safety parameters
and also on quality of life.
In a subgroup of patients the impact of the switch on the body's response to the hormone
insulin will also be measured (Euglycaemic clamp sub group)
Phase:
Phase 4
Details
Lead Sponsor:
St Stephens Aids Trust
Treatments:
Darunavir HIV Protease Inhibitors Protease Inhibitors Ritonavir